当前位置:首页 - 行情中心 - 宣泰医药(688247) - 财务分析 - 利润表

宣泰医药

(688247)

  

流通市值:31.46亿  总市值:31.46亿
流通股本:4.53亿   总股本:4.53亿

利润表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、营业总收入282,579,550.28191,160,204.9294,546,671.06446,568,888.08
  营业收入282,579,550.28191,160,204.9294,546,671.06446,568,888.08
二、营业总成本265,321,926.33173,790,467.0882,432,049.12394,329,144.83
  营业成本167,385,388.52111,768,168.2157,696,405.85270,542,117.19
  税金及附加2,440,029.821,679,123.11936,899.053,383,378.44
  销售费用10,009,568.375,895,390.842,247,487.029,868,874.61
  管理费用29,324,734.4719,443,847.858,343,884.637,131,600.71
  研发费用53,135,865.7631,998,413.6211,973,009.8874,939,615.69
  财务费用3,026,339.393,005,523.451,234,362.72-1,536,441.81
  其中:利息费用1,013.1533.7781.741,411.72
  其中:利息收入2,410,323.921,906,322.171,475,052.15,320,657.35
三、其他经营收益
  加:公允价值变动收益---1,341,275.35
  加:投资收益14,105,650.797,715,066617,185.259,911,414.57
  资产减值损失(新)-2,290,592.29-891,116.42-238,144.97-17,539,733.26
  信用减值损失(新)3,496,549.372,988,454.541,468,545.63-1,453,006.6
  其他收益3,266,126.362,767,356.1962,574.7110,819,130.92
四、营业利润35,835,358.1829,949,498.0614,924,782.5655,318,824.23
  加:营业外收入3,473,019.913,470,415.293,468,974.837,308.85
  减:营业外支出2,992,773.581,288,254.7418,460.712,020,799.66
五、利润总额36,315,604.5132,131,658.6118,375,296.6553,335,333.42
  减:所得税费用2,235,072.292,429,880.661,811,958.45,852,518.73
六、净利润34,080,532.2229,701,777.9516,563,338.2547,482,814.69
(一)按经营持续性分类
  持续经营净利润34,080,532.2229,701,777.9516,563,338.2547,482,814.69
(二)按所有权归属分类
  归属于母公司股东的净利润34,080,532.2229,701,777.9516,563,338.2547,482,814.69
  扣除非经常损益后的净利润24,743,488.4720,377,532.1812,491,038.4231,333,993.96
七、每股收益
  (一)基本每股收益0.080.070.040.11
  (二)稀释每股收益0.080.070.040.11
八、其他综合收益-32,444.69-32,756.85-16,043.8-20,861.17
  归属于母公司股东的其他综合收益-32,444.69-32,756.85-16,043.8-20,861.17
九、综合收益总额34,048,087.5329,669,021.116,547,294.4547,461,953.52
  归属于母公司股东的综合收益总额34,048,087.5329,669,021.116,547,294.4547,461,953.52
公告日期2026-10-292026-08-282026-04-302026-04-30
审计意见(境内)标准无保留意见
TOP↑